Enhancing Self Care Among Oral Cancer Survivors Using a Digital Approach: The Empowered Survivor Trial.

PsychooncologySep 1, 2026
Clinical ResearchOncology (Medical)Open access

Sharon L Manne, Shawna V Hudson, Janet H Van Cleave et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of the Empowered Survivor (ES) digital intervention in enhancing self-efficacy and self-care among 643 oral and oropharyngeal cancer survivors. Results indicated that participants in the ES group reported significantly greater self-efficacy and increased self-care activities, such as oral self-exams and mobility exercises, compared to those in the Generic Online Intervention group.

Key findings

  • Participants in the ES group reported greater self-efficacy at 2 months (p = 0.003) and 6 months (p < 0.001).
  • The ES group showed increased self-care activities, including oral self-exams and mobility exercises.

Why it matters

Enhancing self-efficacy and self-care in cancer survivors can lead to improved health-related quality of life and better management of physical and psychosocial challenges, which are common in this population.

Source

PubMed · PMID 42655903Free full text on PubMed Central

Published in Psychooncology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.